Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890180 | 0.86 | AKR1C1 (0.57) | AKR1C1OPRD1CA12CA1CA2 | |
| SCHEMBL3291673 | 0.85 | AKR1C1 (0.68) | AKR1C1HDAC4HSD11B1ALOX15MEN1 | |
| SCHEMBL3737199 | 0.82 | AKR1C1 (0.70) | AKR1C1OPRD1CA12CA1CA2 | |
| SCHEMBL12928712 | 0.82 | AKR1C1 (0.64) | AKR1C1OPRD1CA12CA1CA2 | |
| SCHEMBL7864618 | 0.81 | AKR1C1 (0.48) | AKR1C1OPRD1HDAC4HSD11B1OPRM1 | |
| SCHEMBL1838291 | 0.81 | AKR1C1 (0.68) | AKR1C1HDAC4HSD11B1P2RX7APOBEC3A | |
| SCHEMBL3129351 | 0.81 | SLC18A3 (0.52) | AKR1C1OPRD1HDAC4OPRM1APOBEC3A | |
| SCHEMBL11627952 | 0.79 | HDAC4 (0.72) | AKR1C1HDAC4LMNANPSR1ALDH1A1 | |
| SCHEMBL2200070 | 0.78 | AKR1C1 (0.42) | AKR1C1OPRD1HDAC4OPRM1APOBEC3A | |
| SCHEMBL24780844 | 0.78 | ALDH1A1 (0.62) | AKR1C1OPRD1LMNANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641758-B1 | DIPHENYLPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI AVENTIS (FR) | 2008-10-29 | — | — | EP | claimed |
| US-7345059-B2 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-03-18 | — | — | US | claimed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| US-20060189664-A1 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-08-24 | — | — | US | claimed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-10479790-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2019-11-19 | — | — | US | disclosed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180305360-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2018-10-25 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10035799-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2018-07-31 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-0863899-A1 | PYRIDOPYRIMIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1998-09-16 | — | — | EP | disclosed |
| EP-0808303-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | disclosed |
| US-5668131-A | CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-09-16 | — | — | US | disclosed |
| WO-1997019946-A1 | PYRIDOPYRIMIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-06-05 | — | — | WO | disclosed |
| EP-0731801-A1 | SUBSTITUTED AMINOALKYLAMINOPYRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996024582-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1996-08-15 | — | — | WO | disclosed |
| WO-1996000224-A1 | 4-S- AND N-SUBSTITUTED 6-ALKYLPYRIDINES FOR CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1996-01-04 | — | — | WO | disclosed |
| WO-1995015324-A1 | SUBSTITUTED AMINOALKYLAMINOPYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | AKR1C1 844/4885OPRD1 4402/4885CA12 197/4885 |
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | AKR1C1 4164/4885OPRD1 2161/4885CA12 4401/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | AKR1C1 4164/4885OPRD1 2161/4885CA12 4401/4885 |
| US-20060189664-A1 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | CNR1, HDAC10, AKR1B10 | AKR1C1 26/4885OPRD1 19/4885CA12 1300/4885 |
| US-10035799-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | AKR1C1 779/4885OPRD1 64/4885CA12 3982/4885 |
| US-20180305360-A1 | COMT Inhibiting Methods and Compositions | COMT, SLC6A3, MAOA | AKR1C1 779/4885OPRD1 64/4885CA12 3982/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | AKR1C1 4164/4885OPRD1 2161/4885CA12 4401/4885 |
| US-10479790-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | AKR1C1 779/4885OPRD1 64/4885CA12 3982/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | AKR1C1 4164/4885OPRD1 2161/4885CA12 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.